Effect of Regorafenib on Digoxin and Rosuvastatin in Patients With Advanced Solid Malignant Tumors.

NCT02106845 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

42

Enrollment

INDUSTRY

Sponsor class

Conditions

Neoplasms

Interventions

DRUG: Digoxin
DRUG: Rosuvastatin
DRUG: Regorafenib (Stivarga, BAY73-4506)

Sponsor

Bayer